A PILOT STUDY TO EVALUATE THE ROLE OF HIGH-DOSE RANIBIZUMAB (2.0MG) IN THE MANAGEMENT OF AMD IN PATIENTS WITH PERSISTENT/RECURRENT MACULAR FLUID LESS THAN 30 DAYS FOLLOWING TREATMENT WITH INTRAVITREAL ANTI-VEGF THERAPY (THE LAST STUDY):